Breaking Finance News

BidaskClub upgraded CytomX Therapeutics Inc (NASDAQ:CTMX) to Hold in a report released today.

BidaskClub has upgraded CytomX Therapeutics Inc (NASDAQ:CTMX) to Hold in a report released on 7/8/2017.

Yesterday CytomX Therapeutics Inc (NASDAQ:CTMX) traded 0.94% higher at $16.18. The company’s 50-day moving average is $14.70 and its 200-day moving average is $14.50. The last stock close price is up -3.62% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 159,504 shares of the stock were exchanged, down from an average trading volume of 230,495

See Chart Below

CytomX Therapeutics Inc (NASDAQ:CTMX)

CytomX Therapeutics Inc has a 52 week low of $9.85 and a 52 week high of $20.02 The company’s market cap is currently $0.

About CytomX Therapeutics Inc (NASDAQ:CTMX)

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.